Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

A. Hochhaus, S. G. O'Brien, F. Guilhot, Brian Druker, S. Branford, L. Foroni, J. M. Goldman, M. C. Müller, J. P. Radich, M. Rudoltz, M. Mone, I. Gathmann, T. P. Hughes, R. A. Larson

Research output: Contribution to journalArticle

663 Citations (Scopus)

Abstract

Imatinib mesylate is considered standard of care for first-line treatment of chronic phase chronic myeloid leukemia (CML-CP). In the phase III, randomized, open-label International Randomized Study of Interferon vs STI571 (IRIS) trial, previously untreated CML-CP patients were randomized to imatinib (n = 553) or interferon-α (IFN) plus cytarabine (n = 553). This 6-year update focuses on patients randomized to receive imatinib as first-line therapy for newly diagnosed CML-CP. During the sixth year of study treatment, there were no reports of disease progression to accelerated phase (AP) or blast crisis (BC). The toxicity profile was unchanged. The cumulative best complete cytogenetic response (CCyR) rate was 82%; 63% of all patients randomized to receive imatinib and still on study treatment showed CCyR at last assessment. The estimated event-free survival at 6 years was 83%, and the estimated rate of freedom from progression to AP and BC was 93%. The estimated overall survival was 88% - or 95% when only CML-related deaths were considered. This 6-year update of IRIS underscores the efficacy and safety of imatinib as first-line therapy for patients with CML.

Original languageEnglish (US)
Pages (from-to)1054-1061
Number of pages8
JournalLeukemia
Volume23
Issue number6
DOIs
StatePublished - 2009

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interferons
Blast Crisis
Cytogenetics
Therapeutics
Leukemia, Myeloid, Chronic Phase
Cytarabine
Standard of Care
Imatinib Mesylate
Disease-Free Survival
Disease Progression
Safety
Survival

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Hochhaus, A., O'Brien, S. G., Guilhot, F., Druker, B., Branford, S., Foroni, L., ... Larson, R. A. (2009). Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia, 23(6), 1054-1061. https://doi.org/10.1038/leu.2009.38

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. / Hochhaus, A.; O'Brien, S. G.; Guilhot, F.; Druker, Brian; Branford, S.; Foroni, L.; Goldman, J. M.; Müller, M. C.; Radich, J. P.; Rudoltz, M.; Mone, M.; Gathmann, I.; Hughes, T. P.; Larson, R. A.

In: Leukemia, Vol. 23, No. 6, 2009, p. 1054-1061.

Research output: Contribution to journalArticle

Hochhaus, A, O'Brien, SG, Guilhot, F, Druker, B, Branford, S, Foroni, L, Goldman, JM, Müller, MC, Radich, JP, Rudoltz, M, Mone, M, Gathmann, I, Hughes, TP & Larson, RA 2009, 'Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia', Leukemia, vol. 23, no. 6, pp. 1054-1061. https://doi.org/10.1038/leu.2009.38
Hochhaus, A. ; O'Brien, S. G. ; Guilhot, F. ; Druker, Brian ; Branford, S. ; Foroni, L. ; Goldman, J. M. ; Müller, M. C. ; Radich, J. P. ; Rudoltz, M. ; Mone, M. ; Gathmann, I. ; Hughes, T. P. ; Larson, R. A. / Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. In: Leukemia. 2009 ; Vol. 23, No. 6. pp. 1054-1061.
@article{9113808be85140e288b29ca80059364e,
title = "Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia",
abstract = "Imatinib mesylate is considered standard of care for first-line treatment of chronic phase chronic myeloid leukemia (CML-CP). In the phase III, randomized, open-label International Randomized Study of Interferon vs STI571 (IRIS) trial, previously untreated CML-CP patients were randomized to imatinib (n = 553) or interferon-α (IFN) plus cytarabine (n = 553). This 6-year update focuses on patients randomized to receive imatinib as first-line therapy for newly diagnosed CML-CP. During the sixth year of study treatment, there were no reports of disease progression to accelerated phase (AP) or blast crisis (BC). The toxicity profile was unchanged. The cumulative best complete cytogenetic response (CCyR) rate was 82{\%}; 63{\%} of all patients randomized to receive imatinib and still on study treatment showed CCyR at last assessment. The estimated event-free survival at 6 years was 83{\%}, and the estimated rate of freedom from progression to AP and BC was 93{\%}. The estimated overall survival was 88{\%} - or 95{\%} when only CML-related deaths were considered. This 6-year update of IRIS underscores the efficacy and safety of imatinib as first-line therapy for patients with CML.",
author = "A. Hochhaus and O'Brien, {S. G.} and F. Guilhot and Brian Druker and S. Branford and L. Foroni and Goldman, {J. M.} and M{\"u}ller, {M. C.} and Radich, {J. P.} and M. Rudoltz and M. Mone and I. Gathmann and Hughes, {T. P.} and Larson, {R. A.}",
year = "2009",
doi = "10.1038/leu.2009.38",
language = "English (US)",
volume = "23",
pages = "1054--1061",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

AU - Hochhaus, A.

AU - O'Brien, S. G.

AU - Guilhot, F.

AU - Druker, Brian

AU - Branford, S.

AU - Foroni, L.

AU - Goldman, J. M.

AU - Müller, M. C.

AU - Radich, J. P.

AU - Rudoltz, M.

AU - Mone, M.

AU - Gathmann, I.

AU - Hughes, T. P.

AU - Larson, R. A.

PY - 2009

Y1 - 2009

N2 - Imatinib mesylate is considered standard of care for first-line treatment of chronic phase chronic myeloid leukemia (CML-CP). In the phase III, randomized, open-label International Randomized Study of Interferon vs STI571 (IRIS) trial, previously untreated CML-CP patients were randomized to imatinib (n = 553) or interferon-α (IFN) plus cytarabine (n = 553). This 6-year update focuses on patients randomized to receive imatinib as first-line therapy for newly diagnosed CML-CP. During the sixth year of study treatment, there were no reports of disease progression to accelerated phase (AP) or blast crisis (BC). The toxicity profile was unchanged. The cumulative best complete cytogenetic response (CCyR) rate was 82%; 63% of all patients randomized to receive imatinib and still on study treatment showed CCyR at last assessment. The estimated event-free survival at 6 years was 83%, and the estimated rate of freedom from progression to AP and BC was 93%. The estimated overall survival was 88% - or 95% when only CML-related deaths were considered. This 6-year update of IRIS underscores the efficacy and safety of imatinib as first-line therapy for patients with CML.

AB - Imatinib mesylate is considered standard of care for first-line treatment of chronic phase chronic myeloid leukemia (CML-CP). In the phase III, randomized, open-label International Randomized Study of Interferon vs STI571 (IRIS) trial, previously untreated CML-CP patients were randomized to imatinib (n = 553) or interferon-α (IFN) plus cytarabine (n = 553). This 6-year update focuses on patients randomized to receive imatinib as first-line therapy for newly diagnosed CML-CP. During the sixth year of study treatment, there were no reports of disease progression to accelerated phase (AP) or blast crisis (BC). The toxicity profile was unchanged. The cumulative best complete cytogenetic response (CCyR) rate was 82%; 63% of all patients randomized to receive imatinib and still on study treatment showed CCyR at last assessment. The estimated event-free survival at 6 years was 83%, and the estimated rate of freedom from progression to AP and BC was 93%. The estimated overall survival was 88% - or 95% when only CML-related deaths were considered. This 6-year update of IRIS underscores the efficacy and safety of imatinib as first-line therapy for patients with CML.

UR - http://www.scopus.com/inward/record.url?scp=67349233062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349233062&partnerID=8YFLogxK

U2 - 10.1038/leu.2009.38

DO - 10.1038/leu.2009.38

M3 - Article

VL - 23

SP - 1054

EP - 1061

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 6

ER -